Home>Topics>Companies>Baxter International

Baxter International BAX

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. Headlines
    1. Long-acting version of Baxter's hemophilia drug succeeds in study

      Headlines

      Thu, 21 Aug 2014

      Aug 21 (Reuters) - Baxter International Inc said a more potent version of its flagship blood disorder drug Advate met the main goal in a late-stage study.

    2. Baxter hemophilia drug successful in Phase 3 trial

      Headlines

      Thu, 21 Aug 2014

      clinical trial evaluating the safety and efficacy of Baxter International 's ( BAX +0.9% ) BAX 855 , an extended half-life recombinant factor ..... on-demand group (1.9 vs. 41.5, respectively). BAX 855 was also effective in treating bleeding episodes

    3. Baxter Remains Undervalued as BAX 855 Appears on Track for U.S. Launch in 2015

      Commentary

      Thu, 21 Aug 2014

      Baxter has reported positive ..... Phase III study of BAX 855, a twice-weekly ..... particularly given that BAX 855 is now one step ..... committee review of Baxter 's differentiated ..... for the stock. Baxter 's wide, stable ..... patients taking BAX 855 as a twice-weekly

    4. New Morningstar Analyst Report for CSL Limited

      Stock Reports

      Wed, 13 Aug 2014

      directors have deep experience in the international pharmaceuticals industry, while the remaining directors have a range ..... of the three biggest industry players, along with Baxter International of the U.S. and Grifols of Spain. These three

    5. Baxter International : A Spin-Off Play And An Increasing Dividend

      Headlines

      Tue, 12 Aug 2014

      By Northport Investments : Baxter International (NYSE: BAX ) is a company that is entering ..... safe stock" without any risk, BAX shares are relatively safe in comparison ..... portfolio. With the split of BAX into 2 companies approaching in

    6. Update: China Biologic Products - Strong Q2 Earnings Growth

      Headlines

      Wed, 6 Aug 2014

      However, there are underlying risks to an investment in China Biologic, given that the plasma space is home to Baxter (NYSE: BAX ) and Novo Nordisk (NYSE: NVO ), which market internationally ADVATE and NovoSeven, NovoEight and NovoThirteen

    7. Momenta Pharmaceuticals Heading For A Repeat

      Headlines

      Tue, 5 Aug 2014

      all resources to development of new drugs, Momenta Pharmaceuticals (NASDAQ: MNTA ) is adopting a fairly unusual strategy ..... jucier margins in return. Deep-pocketed partners Baxter (NYSE: BAX ) and Novartis (NYSE: NVS ) are eager to exploit

    8. FDA clears Flexbumin 5% Solution

      Headlines

      Mon, 4 Aug 2014

      The U.S. regulator approves Baxter International 's ( BAX -1% ) Flexbumin 5% Solution indicated for hypovolemia , hypoalbuminemia due to general causes, burns and in patients undergoing

    9. Update: Baxter's Earnings Beat Reaffirms Bull Thesis

      Headlines

      Fri, 1 Aug 2014

      June I wrote a bullish article on Baxter (NYSE: BAX ), with a thesis stating that the ..... also stated that the expansion of Baxter 's ADVATE program into emerging ..... there are underlying risks to a Baxter investment, given that the company

    10. UPDATE 2-FDA panel: Benefit of Baxter's immune therapy outweighs risk

      Headlines

      Thu, 31 Jul 2014

      WASHINGTON, July 31 (Reuters) - The benefit of Baxter International Inc 's experimental immune deficiency therapy, HyQvia, outweighs the risks, an advisory committee to the U.S. Food and Drug Administration concluded on Thursday.

    « Prev12345Next »
    Content Partners